ArticleMolecules (Basel, Switzerland)2022
The Impact of Software Used and the Type of Target Protein on Molecular Docking Accuracy.
Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 74 citations in OpenAlex.
- Identification of spiropyrrolidinoxindoles as SARS-CoV-2 main protease inhibitor hits from virtual screening.Journal of computer-aided molecular design · 2026Article
- Hypericin and berberine promote elongation of hair peg-like sprouting in hair follicle organoids via oxytocin signaling activation.Scientific reports · 2026Article
- Prediction of primary human targets and toxicity mechanisms of imidacloprid using integrativeToxicology reports · 2026Article
- Dual-mode NRSC advances · 2026Article
- Integrative structural and physicochemical characterization of chalcone synthase enzymes from medicinal plants using AlphaFold, molecular docking, and molecular dynamics.Scientific reports · 2026Article
- Anti-Inflammatory Activity ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Virtual Screening of FDA-Approved Compounds: Exploring New Alternatives for HIV Treatment.ACS omega · 2026Article
- In silico and in vitro investigations of novel Siglec-1 inhibitors in a microglial cell model.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- AI accelerate the identification of druggable targets by 3D structures of proteins and compounds.NPJ precision oncology · 2026Review
- Antibody screening for tumor and immune hotspot targets: The frontier of new methods and technologies.Journal of pharmaceutical analysis · 2026Review
- Article
- Effect of atrazine and curcumin on mouse I-10 Leydig cells: steroidogenesis and beyond.Frontiers in endocrinology · 2026Article
- Rhein ameliorates MASH via EGFR/AKT/PPARα-mediated coordinated regulation of metabolism and inflammation.Frontiers in pharmacology · 2026Article
- A roadmap to unveil the mechanism(s) of natural indole-derived molecules against NAFLD-derived HCC via systems pharmacology.Translational oncology · 2026Article
- Integrative in vitro and in silico evaluation of HSP60-derived peptides as immunomodulators of the TLR4/MD-2 complex.Scientific reports · 2025Article
- Structure-Based Identification of Natural Inhibitors Targeting the Gc Glycoprotein of Oropouche Virus: An In Silico Approach.International journal of molecular sciences · 2025Article
- Molecular Mechanism Discovery of Acacetin Against Cancers: Insights from Network Pharmacology and Molecular Docking.International journal of molecular sciences · 2025Review
- Quercetin and Its Structural Analogs as NUDT5 Inhibitors: A Preliminary In Silico Study.International journal of molecular sciences · 2025Article
- Analysis of NUDIX enzymes across fungi reveals previously unrecognized diversity.BMC genomics · 2025Article
- Utilizing ADMET Analysis and Molecular Docking to Elucidate the Neuroprotective Mechanisms of a Cannabis-Containing Herbal Remedy (Suk-Saiyasna) in Inhibiting Acetylcholinesterase.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The modern development of computer technology and different in silico methods have had an increasing impact on the discovery and development of new drugs. Different molecular docking techniques most widely used in silico methods in drug discovery. Currently, the time and financial costs for the initial hit identification can be significantly reduced due to the ability to perform high-throughput virtual screening of large compound libraries in a short time. However, the selection of potential hit compounds still remains more of a random process, because there is still no consensus on what the binding energy and ligand efficiency (LE) of a potentially active compound should be. In the best cases, only 20-30% of compounds identified by molecular docking are active in biological tests. In this work, we evaluated the impact of the docking software used as well as the type of the target protein on the molecular docking results and their accuracy using an example of the three most popular programs and five target proteins related to neurodegenerative diseases. In addition, we attempted to determine the "reliable range" of the binding energy and LE that would allow selecting compounds with biological activity in the desired concentration range.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.